AryoGen


AryoGen Pharmed is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.

History

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was created by a group of scientific experts spun off a well versed Biopharmaceutical company, which formed a totally new entity christened as AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest due to the importance of the target products on Iran's community health care system, as well as its impact in the region and around the world.
AryoGen is the world's first company to produce biosimilar Blood Coagulation Factor VII, which required a 50 million Euros product investment. Also AryoGen has established a monoclonal antibody production line, making it one of only 10 manufacturers in the world.
AryoGen changed its name to AryoGen Pharmed in 2016.
AryoGen Pharmed has received a Good Manufacturing Practice certificate from the , becoming one of the first monoclonal antibody manufacturers in the Middle East and North Africa region to be certified.

Products

AryoGen's products include:
AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.